Zai Lab’s Zoci combination achieves 81.8% response rate in first-line lung cancer trial
ZLAB•Zai Lab reported an 81.8% response rate in a Phase 1b trial of zocilurtatug pelitecan with atezolizumab for first-line extensive-stage small cell lung cancer.
1. Trial results
Zai Lab reported encouraging responses with zocilurtatug pelitecan combined with atezolizumab in a Phase 1b trial for first-line extensive-stage small cell lung cancer. The platinum-free combination showed durable responses and was generally well tolerated; adding carboplatin led to more frequent severe adverse events. Results are scheduled for presentation at the European Society for Medical Oncology Congress on October 26, 2026.
2. Next trial
A global randomized Phase 3 trial evaluating zocilurtatug pelitecan with an immuno-oncology regimen is expected to begin by year-end 2026.
